The development map
AI belongs inside a development strategy that accounts for the material, people, and evidence the product needs. Each result helps refine what to do next.
For an early liquid biopsy company, access to suitable samples can determine which questions are answerable. Cohort composition, clinical context, consent, metadata, and follow-up all shape what a study can support.
Connect acquisition priorities to assay development and the intended evidence plan. Computational tools can support that work; suitable specimens and well-designed studies remain essential.
Focus analysis and automation on decisions: which experiment to run, which uncertainty to resolve, and which result deserves another look. Consider sample consumption, reagent costs, and scientific review alongside turnaround time.
Bring intended claims, validation, data provenance, and documentation into early technical decisions. Work with the relevant specialists on FDA pathways, MolDX evidence expectations, and CAP/CLIA laboratory requirements as applicable.
For workflows involving protected health information, address HIPAA obligations, access controls, and vendor data handling with privacy and compliance leads.
Make the next milestone a shared scientific, technical, and business decision.
Talk through your development plan